$18.600
+0.253 (+1.36%)收盤時
- 最高
- 20.000
- 開盤
- 19.020
- 成交量加權均價
- 19.00
- 成交量
- 11.96K
- 市值
- —
- 最低
- 18.400
- 成交金額
- 227.20K
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways. The company was incorporated in 2025 and is based in Sacramento, California.
估值指標
MTRI 常見問題 —— 由 Alphio AI 解答
Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways. The company was incorporated in 2025 and is based in Sacramento, California.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- Dollar-Cost Averaging vs Lump Sum: How to Invest Cash in a Volatile, High-Yield 2026 MarketDollar cost averaging vs lump sum in a volatile 2026 market: what Vanguard's research shows, how 4%+ T-bill yields change the math, and how to build a plan.
- Stock Market Outlook 2027: What Wall Street's S&P 500 Forecasts Really Tell InvestorsStock market outlook 2027: what Goldman, UBS, BofA and bears forecast for the S&P 500, the earnings math behind targets, and how to plan for any scenario.
- REITs and Rising Interest Rates in 2026: Why Real Estate Stocks Are Holding Up and Where the Risks AHow rising interest rates affect REITs in 2026: why REITs are up despite Fed hikes, which sectors hold up, how to value REITs and build a rate-aware allocation.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。